Risks and responses to disease rebound after discontinuation of ceritinib

Ceritinib/Ceritinib As an important targeted therapy for ALK-positive non-small cell lung cancer, it has shown significant efficacy in maintaining tumor stability and delaying progression. However, since it cannot cure the tumor, once the drug is discontinued, especially when the tumor is not fully controlled or the resistance mechanism is not clear, patients face a higher risk of rapid disease rebound. This rebound is mainly manifested by tumor progression, the emergence of new metastases, or significant aggravation of symptoms, indicating that the disease rapidly enters an active progression phase from a drug-resistant state.

The reason for rebound may be related to the dependence of tumors onALK inhibition. Ceritinib inhibits the ALK signaling pathway. Once the inhibition is removed, tumor cells can reactivate this pathway and quickly resume growth. Another mechanism is that latent drug-resistant mutations that have existed during treatment rapidly amplify and dominate after drug withdrawal, contributing to the worsening of the disease.

Coping strategies should first prevent patients from stopping medication on their own or frequently interrupting treatment. If a short-term suspension is required due to adverse reactions, the risks should be assessed under the guidance of a doctor and treatment should be resumed as soon as possible. For patients who have rebounded, it is necessary to combine the molecular testing results to determine whether there is an ALK mutation or activation of the bypass pathway, and then decide whether to continue using ceritinib, switch to a third-generation ALK inhibitor such as lorlatinib, or combine other targeted drugs and chemotherapy regimens.

In addition, during long-term treatment, it is recommended to conduct imaging evaluation and monitor tumor gene status every 2-3 months, and dynamically adjust treatment strategies. Multidisciplinary consultation (MDT) also has important reference value in assessing the feasibility of drug discontinuation. Patients should fully understand the importance of continued drug treatment and establish a good communication mechanism with doctors to handle drug-related issues in a timely manner, minimize the risk of rebound, and prolong disease control time.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib